New recurrent UTI guideline: What urologists need to know
The AUA/CUA/SUFU guide focuses on a combination of symptoms and positive cultures.
The AUA/CUA/SUFU guide focuses on a combination of symptoms and positive cultures.
“What we’re really trying to see now is this integration of imaging and using it with respect to AI and planning,” says Dean S. Elterman,…
“Taken altogether, the study remains positive for PFS, but not for overall survival,” says Laurence Albiges, MD, PhD.
“Over 80% of patients…had at least 2 lines of therapy, so this is a heavily refractory population,” said Toni K. Choueiri, MD, FASCO.
“These data reinforce enfortumab vedotin and pembrolizumab as the new standard of care in frontline urothelial cancer,” says Thomas Powles, MD, PhD.
“The efficacy findings reported to date are 71% any time response,” says John A. Taylor III, MD, MS.
The median number of re-injections was 6 (range, 1-12).
“For the MIRAGE trial specifically, we’re going to continue following patients and we’ll look at [data at] 5 years as well,” says Amar U. Kishan,…
The median duration of response was 47.8 months among patients who achieved an initial complete response.
“I think targeting things that make communities more vulnerable would be reasonable things to target to try and affect disease practices,” says William Furuyama, MD.
“While I would hesitate to say that reversal is truly better in terms of efficacy, I think this data suggests that it’s at least as…